Fedratinib for patients with myelofibrosis

Ruben Van Dijck^*, John John Schnog, Peter te Boekhorst

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Access to Document

@article{adc247c1050243148b536e54419296d2,

title = "Fedratinib for patients with myelofibrosis",

author = "{Van Dijck}, Ruben and Schnog, {John John} and {te Boekhorst}, Peter",

year = "2025",

month = apr,

doi = "10.1016/s2352-3026(24)00398-3",

language = "English",

volume = "12",

journal = "The Lancet Haematology",

issn = "2451-9960",

publisher = "Lancet Publishing Group",

number = "4",

}

TY - JOUR

T1 - Fedratinib for patients with myelofibrosis

AU - Van Dijck, Ruben

AU - Schnog, John John

AU - te Boekhorst, Peter

PY - 2025/4

Y1 - 2025/4

UR - http://www.scopus.com/inward/record.url?scp=105001231504&partnerID=8YFLogxK

U2 - 10.1016/s2352-3026(24)00398-3

DO - 10.1016/s2352-3026(24)00398-3

M3 - Comment/Letter to the editor

C2 - 40174994

AN - SCOPUS:105001231504

SN - 2451-9960

VL - 12

JO - The Lancet Haematology

JF - The Lancet Haematology

IS - 4

M1 - e240

ER -